Literature DB >> 22308434

Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.

Emilie A Bard-Chapeau1, Justin Jeyakani, Chung H Kok, Julius Muller, Belinda Q Chua, Jayantha Gunaratne, Arsen Batagov, Piroon Jenjaroenpun, Vladimir A Kuznetsov, Chia-Lin Wei, Richard J D'Andrea, Guillaume Bourque, Nancy A Jenkins, Neal G Copeland.   

Abstract

Ecotropic viral integration site 1 (EVI1) is an oncogenic dual domain zinc finger transcription factor that plays an essential role in the regulation of hematopoietic stem cell renewal, and its overexpression in myeloid leukemia and epithelial cancers is associated with poor patient survival. Despite the discovery of EVI1 in 1988 and its emerging role as a dominant oncogene in various types of cancer, few EVI1 target genes are known. This lack of knowledge has precluded a clear understanding of exactly how EVI1 contributes to cancer. Using a combination of ChIP-Seq and microarray studies in human ovarian carcinoma cells, we show that the two zinc finger domains of EVI1 bind to DNA independently and regulate different sets of target genes. Strikingly, an enriched fraction of EVI1 target genes are cancer genes or genes associated with cancer. We also show that more than 25% of EVI1-occupied genes contain linked EVI1 and activator protein (AP)1 DNA binding sites, and this finding provides evidence for a synergistic cooperative interaction between EVI1 and the AP1 family member FOS in the regulation of cell adhesion, proliferation, and colony formation. An increased number of dual EVI1/AP1 target genes are also differentially regulated in late-stage ovarian carcinomas, further confirming the importance of the functional cooperation between EVI1 and FOS. Collectively, our data indicate that EVI1 is a multipurpose transcription factor that synergizes with FOS in invasive tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22308434      PMCID: PMC3277513          DOI: 10.1073/pnas.1119229109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia.

Authors:  S Ogawa; M Kurokawa; T Tanaka; K Tanaka; A Hangaishi; K Mitani; N Kamada; Y Yazaki; H Hirai
Journal:  Leukemia       Date:  1996-05       Impact factor: 11.528

2.  The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas.

Authors:  Björn Koos; Sebastian Bender; Hendrik Witt; Sonja Mertsch; Jörg Felsberg; Rudi Beschorner; Andrey Korshunov; Barbara Riesmeier; Stefan Pfister; Werner Paulus; Martin Hasselblatt
Journal:  Clin Cancer Res       Date:  2011-04-14       Impact factor: 12.531

3.  Identification of binding sites of EVI1 in mammalian cells.

Authors:  Bogdan Yatsula; Sharon Lin; Andrew J Read; Amanda Poholek; Kristin Yates; Dongxian Yue; Pei Hui; Archibald S Perkins
Journal:  J Biol Chem       Date:  2005-07-08       Impact factor: 5.157

4.  Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.

Authors:  Hiromi Yuasa; Yuichi Oike; Atsushi Iwama; Ichiro Nishikata; Daisuke Sugiyama; Archibald Perkins; Michael L Mucenski; Toshio Suda; Kazuhiro Morishita
Journal:  EMBO J       Date:  2005-05-12       Impact factor: 11.598

5.  Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.

Authors:  Meera Nanjundan; Yasuhisa Nakayama; Kwai Wa Cheng; John Lahad; Jinsong Liu; Karen Lu; Wen-Lin Kuo; Karen Smith-McCune; David Fishman; Joe W Gray; Gordon B Mills
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

6.  Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells.

Authors:  Leopoldo Laricchia-Robbio; Raffaella Fazzina; Donglan Li; Ciro R Rinaldi; Kisaly K Sinha; Soumen Chakraborty; Giuseppina Nucifora
Journal:  Mol Cell Biol       Date:  2006-09-05       Impact factor: 4.272

7.  Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung.

Authors:  Yong-Woo Choi; Jin Soo Choi; Long Tai Zheng; Yun Jeong Lim; Hyoung Kyu Yoon; Yeul Hong Kim; Young-Pil Wang; Young Lim
Journal:  Lung Cancer       Date:  2006-11-15       Impact factor: 5.705

Review 8.  EVI1 and hematopoietic disorders: history and perspectives.

Authors:  Giuseppina Nucifora; Leopoldo Laricchia-Robbio; Vitalyi Senyuk
Journal:  Gene       Date:  2005-11-28       Impact factor: 3.688

9.  EVI1 abrogates interferon-alpha response by selectively blocking PML induction.

Authors:  Silvia Buonamici; Donglan Li; Fady M Mikhail; Antonella Sassano; Leonidas C Platanias; Oscar Colamonici; John Anastasi; Giuseppina Nucifora
Journal:  J Biol Chem       Date:  2004-11-01       Impact factor: 5.157

Review 10.  The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.

Authors:  Rotraud Wieser
Journal:  Gene       Date:  2007-04-20       Impact factor: 3.688

View more
  38 in total

1.  The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Authors:  Nina Fenouille; Christopher F Bassil; Issam Ben-Sahra; Lina Benajiba; Gabriela Alexe; Azucena Ramos; Yana Pikman; Amy S Conway; Michael R Burgess; Qing Li; Frédéric Luciano; Patrick Auberger; Ilene Galinsky; Daniel J DeAngelo; Richard M Stone; Yi Zhang; Archibald S Perkins; Kevin Shannon; Michael T Hemann; Alexandre Puissant; Kimberly Stegmaier
Journal:  Nat Med       Date:  2017-02-13       Impact factor: 53.440

2.  Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex.

Authors:  Danton Ivanochko; Levon Halabelian; Elizabeth Henderson; Pavel Savitsky; Harshika Jain; Edyta Marcon; Shili Duan; Ashley Hutchinson; Alma Seitova; Dalia Barsyte-Lovejoy; Panagis Filippakopoulos; Jack Greenblatt; Evelyne Lima-Fernandes; Cheryl H Arrowsmith
Journal:  Nucleic Acids Res       Date:  2019-02-20       Impact factor: 16.971

3.  KEGG orthology-based annotation of the predicted proteome of Acropora digitifera: ZoophyteBase - an open access and searchable database of a coral genome.

Authors:  Walter C Dunlap; Antonio Starcevic; Damir Baranasic; Janko Diminic; Jurica Zucko; Ranko Gacesa; Madeleine Jh van Oppen; Daslav Hranueli; John Cullum; Paul F Long
Journal:  BMC Genomics       Date:  2013-07-26       Impact factor: 3.969

4.  EVI and MDS/EVI are required for adult intestinal stem cell formation during postembryonic vertebrate development.

Authors:  Morihiro Okada; Yun-Bo Shi
Journal:  FASEB J       Date:  2017-09-19       Impact factor: 5.191

5.  Integrated analyses of genome-wide DNA occupancy and expression profiling identify key genes and pathways involved in cellular transformation by a Marek's disease virus oncoprotein, Meq.

Authors:  Sugalesini Subramaniam; John Johnston; Likit Preeyanon; C Titus Brown; Hsing-Jien Kung; Hans H Cheng
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

6.  EVI1 oncoprotein interacts with a large and complex network of proteins and integrates signals through protein phosphorylation.

Authors:  Emilie A Bard-Chapeau; Jayantha Gunaratne; Pankaj Kumar; Belinda Q Chua; Julius Muller; Frederic A Bard; Walter Blackstock; Neal G Copeland; Nancy A Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

7.  Ecotropic viral integration site 1, a novel oncogene in prostate cancer.

Authors:  A Queisser; S Hagedorn; H Wang; T Schaefer; M Konantz; S Alavi; M Deng; W Vogel; A von Mässenhausen; G Kristiansen; S Duensing; J Kirfel; C Lengerke; S Perner
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

8.  Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.

Authors:  A Sayadi; J Jeyakani; S H Seet; C-L Wei; G Bourque; F A Bard; N A Jenkins; N G Copeland; E A Bard-Chapeau
Journal:  Oncogene       Date:  2015-08-03       Impact factor: 9.867

9.  Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma.

Authors:  Minmin Liu; Lian Zhang; Hongtao Li; Toshinori Hinoue; Wanding Zhou; Hitoshi Ohtani; Anthony El-Khoueiry; John Daniels; Casey O'Connell; Tanya B Dorff; Qianjin Lu; Daniel J Weisenberger; Gangning Liang
Journal:  Hepatology       Date:  2018-10       Impact factor: 17.425

10.  EVI1 splice variants modulate functional responses in ovarian cancer cells.

Authors:  Punashi Dutta; Tuyen Bui; Kyle A Bauckman; Khandan Keyomarsi; Gordon B Mills; Meera Nanjundan
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.